Expert review of anti-infective therapyHumansAntiviral AgentsInterferon-alphaPolyethylene GlycolsDrug Therapy
Current evidence of bulevirtide as monotherapy compared to combination treatment with pegylated interferon for hepatitis delta.
Juan Carlos Ruiz-Cobo, Adriana Palom, Mar Riveiro-Barciela, María Buti
Published: 202510.1080/14787210.2025.2578787
Abstract
INTRODUCTION: Pegylated interferon alpha-2a (PEG-IFN) has been used off-label as chronic hepatitis delta (CHD) treatment since the 1990s. However, it has not received formal approval for this indication. Bulevirtide (BLV), a first-in-class entry inhi…
Preview only. Read the full abstract at the source